Sanofi hostile move for Genzyme
05 October 2010
Sanofi-Aventis has taken its $69-per-share (£44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. In response, Genzyme has advised shareholders to hold fast.
Viehbacher is determined that Sanofi's bid will suceed
Sanofi says that it met recently with shareholders representing more than 50 per cent of the Genzyme share total, who were 'frustrated with Genzyme's persistent refusal to have meaningful discussions'. Sanofi chief executive Christopher Viehbacher said: 'Sanofi-Aventis is committed to a transaction with Genzyme, and we believe that our offer reflects both Genzyme's upside potential and its current operational challenges'.
In a conference call, Viehbacher said that Sanofi had no non-public information about the ongoing Genzyme manufacturing problems. In June 2009, Genzyme was forced to temporarily halt production at its Alston Landing site in Massachusetts, US, due to a viral infection. In May, the company said shipments were meeting 50 per cent of the demand for Cerezyme (imiglucerase), for the treatment of Gaucher disease, and 30 per cent for Fabrazyme (agalsidase beta), for the treatment of Fabry disease.
But despite these setbacks, Genzyme remains attractive owing to its pipeline of biologics, while Sanofi is looking to compensate for the expiry of patents for key drugs, such as Plavix (clopidogrel) - for the prevention of stoke and heart attack - and cancer drug Taxotere (docetaxel).
Last month, Sanofi-Aventis and Covance, a US contract research company, signed a deal committing the French drug giant to Covance services worth up to $2.2 billion over the next 10 years.
Interesting? Spread the word using the 'tools' menu on the left.
Also of interest
06 July 2010
It has been over two months since the explosion on BP's Deepwater Horizon oil rig, but what's in store for the company at the eye of the storm?
17 March 2010
CF Industries looks to have won the turf wars after its $4.7 billion bid beats Yara out of the bidding for Terra
27 January 2009
Pfizer snaps up rival pharma firm Wyeth for $68 billion
Comment on this story at the Chemistry World blog
Read other posts and join in the discussion
External links will open in a new browser window